Cargando…
Exacerbating and reversing lysosomal storage diseases: from yeast to humans
Lysosomal storage diseases (LSDs) arise from monogenic deficiencies in lysosomal proteins and pathways and are characterized by a tissue-wide accumulation of a vast variety of macromolecules, normally specific to each genetic lesion. Strategies for treatment of LSDs commonly depend on reduction of t...
Autores principales: | Rajakumar, Tamayanthi, Munkacsi, Andrew B., Sturley, Stephen L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shared Science Publishers OG
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597791/ https://www.ncbi.nlm.nih.gov/pubmed/28913343 http://dx.doi.org/10.15698/mic2017.09.588 |
Ejemplares similares
-
Potential COVID-19 therapeutics from a rare disease: weaponizing
lipid dysregulation to combat viral infectivity
por: Sturley, Stephen L., et al.
Publicado: (2020) -
Identification and characterization of protein interactions with the major Niemann–Pick type C disease protein in yeast reveals pathways of therapeutic potential
por: Hammond, Natalie, et al.
Publicado: (2023) -
Lysosomes and Lysosomal Storage Diseases
por: Noebels, Jeffrey L.
Publicado: (1981) -
Lysosomal storage diseases
por: Ferreira, Carlos R., et al.
Publicado: (2017) -
Biomarkers in Lysosomal Storage Diseases
por: Bobillo Lobato, Joaquin, et al.
Publicado: (2016)